Biotech News

Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Orchard Therapeutics (ORTX)Orchard Therapeutics2026-06-25 13:46 ESTClinical readout

Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today announced the last patient has been treated in a registrational

Open original release

Related news

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Announces Multiple Data Presentations and Publications

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan

ORTXOrchard Therapeutics2026-06-25 13:46 EST

Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Orchard Therapeutics

Orchard Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ORTXOrchard Therapeutics2026-06-26 11:26 EST

Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day

ORTXOrchard Therapeutics2026-06-26 11:26 EST

Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024

ORTXOrchard Therapeutics2026-06-26 11:26 EST

Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

ORTXOrchard Therapeutics2026-06-26 11:26 EST

Orchard Therapeutics Announces Multiple Data Presentations and Publications

ORTXOrchard Therapeutics2026-06-26 11:26 EST

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States